Currently, the mains targets in immunotherapy in clinical transplantation are T cells directed. However, the long term survival of the graft remain challenged by chronic rejection, in which B cells play a significant role, by secreting alloantibodies or by presenting antigen to CD4 T cells. For several years ...
Currently, the mains targets in immunotherapy in clinical transplantation are T cells directed. However, the long term survival of the graft remain challenged by chronic rejection, in which B cells play a significant role, by secreting alloantibodies or by presenting antigen to CD4 T cells. For several years now, this vision has been enlarged, and we know that certain B cells are increasingly implicated as tolerogenic cells, in some process of auto-immune diseases or tolerance. Developing therapeutic strategies that could increase the numbers and the effects of these cells could represent a new key in transplantation and the outcome of graft survival. In this research topic, we propose to discuss different issues concerning B cells in transplantation focusing on B cell biology, B cell antibody production and differentiation and to particularly focus on new advances in regulatory B cells and their possible involvement in graft outcome.We will focus on molecules that have been shown to be involved at different levels of B cell regulation, such as CD5 and a particular attention will be played to discovery of new mechanisms of regulation such as miRNA. Finally, the development of new therapeutic strategies involving B cells will be debated.
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.